RxDoctor Payments Data

Sunil Reddy, MD

Neurology · Tampa, FLNPI 1952368433

Payments from drug & device makers

$22,026in general payments, 2019–2025

Across 1,301 payments — averaging $16.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$4K
  • Amgen$1K
  • Novartis$1K
  • Bristol Myers Squibb$1K
  • Teva Pharmaceuticals USA, Inc.$1K
  • Sanofi$1K
  • plus $12K from 54 others

What the payments were for

  • Consulting fees$230%
  • Speaking & faculty fees$390%
  • Food & beverage$21,75499%
  • Education$2101%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)214$3,631
Amgen(2 entities)70$1,380
Novartis114$1,366
Bristol Myers Squibb69$1,335
Teva Pharmaceuticals USA, Inc.137$1,211
Sanofi50$1,039
UCB, Inc.54$1,010
Genentech USA, Inc.55$871
Biogen43$848
Argenx US, Inc.23$572
Lilly USA, LLC31$550
Takeda Pharmaceuticals U.S.A., Inc.18$509
AstraZeneca(2 entities)26$505
Lundbeck LLC21$470
Pfizer30$466
Neurocrine Biosciences, Inc.18$388
Johnson & Johnson(2 entities)17$366
E.r. Squibb & Sons, L.L.C.17$335
Biohaven Pharmaceuticals, Inc.31$318
Upsher-smith Laboratories LLC14$281
EMD Serono, Inc.14$265
GE HealthCare14$252
CSL Behring12$247
Adamas Pharmaceuticals, Inc.14$234
TG Therapeutics, Inc.8$216
Vanda Pharmaceuticals Inc.10$205
Avanir Pharmaceuticals, Inc.12$198
Eisai Inc.12$193
Merz Pharmaceuticals, LLC9$191
Amneal Pharmaceuticals LLC11$191
Supernus Pharmaceuticals, Inc.17$175
Otsuka America Pharmaceutical, Inc.6$140
Acadia Pharmaceuticals Inc8$137
SK Life Science, Inc.4$133
MDD US Operations, LLC8$125
Cycle Pharmaceuticals Inc6$122
Mallinckrodt Hospital Products Inc.5$109
Sanofi-aventis U.S. LLC6$101
Jazz Pharmaceuticals Inc.5$95
Acorda Therapeutics, Inc4$94
Impel Pharmaceuticals LLC4$89
Axsome Therapeutics, Inc.3$75
Azurity Pharmaceuticals, Inc.4$73
Neurelis, Inc.4$59
Livanova USA, Inc.3$58
Averitas Pharma Inc.3$58
Harmony Biosciences LLC3$53
Arbor Pharmaceuticals, Inc.3$50
Octapharma USA, Inc.2$48
Stimwave Technologies Incorporated2$44
Biohaven Pharmaceutical Holding Company Ltd.3$44
Assertio Therapeutics, Inc.3$42
Scilex Pharmaceuticals Inc.2$41
GRT US Holding, Inc.2$39
Mylan Specialty L.p.1$36
Banner Life Sciences, LLC2$36
Grifols USA, LLC2$36
Merz North America, Inc.2$35
Zyla Life Sciences, Inc.2$28
Akcea Therapeutics, Inc.1$22

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$22,026 in reported general payments places this provider in the 75th percentile of 1,434 neurology providers in Florida.

See all neurology providers in Florida

Medicare billing

Part B allowed, 2024
$994,361
Medicare patients
455
Services billed
36,989

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Aimovig AutoinjectorErenumab-Aooe33$38,536
UbrelvyUbrogepant28$27,950
Nurtec OdtRimegepant Sulfate21$21,371
NeuproRotigotine14$21,153
BotoxOnabotulinumtoxina16$20,652
NeurontinGabapentin16$19,243
Oxtellar XrOxcarbazepine12$12,625
Emgality PenGalcanezumab-Gnlm13$9,333
Carbidopa-LevodopaCarbidopa/Levodopa143$4,190
Ropinirole ErRopinirole Hcl12$3,625
DilantinPhenytoin Sodium Extended15$3,569
Gabapentin251$3,074
Lacosamide18$2,553
Levetiracetam84$1,969
Entacapone27$1,828

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy, Botox$3,631$48,60344 claims
PfizerNurtec Odt, Dilantin$466$24,94036 claims
UCB, Inc.Neupro$1,010$21,15314 claims
Supernus Pharmaceuticals, Inc.Oxtellar Xr$175$12,62512 claims
Amneal Pharmaceuticals LLCPyridostigmine Bromide$191$1,03120 claims
Upsher-smith Laboratories LLCTopiramate$281$70364 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,434 neurology providers in Florida.

Other neurology in Tampa

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →